HAART Adherence: A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators

• Introduction
• Methods
• Results
• Discussion
• References

Introduction

The introduction of antiretroviral therapy (ART) has been credited with extending the lifespan of people living with HIV/AIDS.¹ However, its efficacy relies on access to treatment and excellent adherence, which has proven to be a serious challenge to those receiving highly active antiretroviral therapy (HAART).^2,3 Regimens are often complicated, can require dietary restrictions, and may lead to adverse effects.⁴ Non-adherence to ART in adult populations has been shown to range from 33% to 88%, depending on how adherence is defined and evaluated.⁵ Research indicates that consistently high levels of adherence are necessary for reliable viral suppression^6,7 and prevention of resistance,⁸ disease progression,⁹ and death.¹⁰ As successful treatment requires exceptional adherence to ART, interventions to improve and maintain adherence are needed.

Several studies have been conducted that examine factors affecting adherence to HAART. We used a novel methodology to synthesize the information from these studies by performing a systematic review on all the literature available in this field using content analysis, particularly focusing on the currently existing qualitative studies and examining their generalizability through quantitative data. We examined both developed and developing nation patient populations.¹¹

Methods

Search Strategy

We performed a systematic, all-language literature search for all qualitative studies and quantitative surveys that addressed barriers and motivators influencing adherence to antiretroviral (ARV) regimens in HIV-positive patients. We searched the following databases: AMED (inception to June 2005), Campbell Collaboration (inception to June 2005), CinAhl (inception to June 2005), Cochrane Library (inception to June 2005), Embase (inception to June 2005), ERIC (inception to June 2005), MedLine (inception to June 2005), and NHS EED (inception to June 2005). Unpublished studies were also sought using the search terms "adherence" and "HIV" on www.clinicaltrials.gov, the UK National Research Register, and conference abstracts from international conference Web sites: International AIDS Society conferences (inception to 2005) and Conferences on Retroviruses and Opportunitistic Infections (inception to 2005). Our search strategy combined terms that represented attitudes, barriers, and anxieties. Our search vocabulary included "HIV or AIDS," "compliance or adherence," "factors or determinant or barriers," "motivate or facilitate," and "HAART or antiretroviral." We supplemented this search by reviewing the bibliographies of key papers.

Study Selection

Two members of the study team independently reviewed the abstracts. Eligible studies met the following criteria: 1) reported an original research study, 2) contained content addressing barriers or facilitators to ART adherence, and 3) were either a qualitative study or quantitative survey. The studies were divided to represent developed or developing nations, as according to the United Nations Human Development Index (HDI).¹² The HDI is a composite index that measures a country's average achievements in three basic aspects of human development: longevity, knowledge, and standard of living.

Data Extraction

Two reviewers independently extracted data and appraised both quality and content. From an initial review of qualitative studies, a coding template was iteratively developed to categorize key barriers to adherence to HAART. The reviewers then conducted a second review of the papers and identified whether they contained the barriers present in the complete template. At each stage of the data abstraction, the reviewers discussed the studies to determine consensus regarding the identification and coding of themes. We analyzed the themes presented in the qualitative studies. After the initial viewing of the selected articles, these themes were grouped into categories. Barriers and facilitators fell under the following subheadings: 1) patient-related, 2) beliefs about medication, 3) daily schedules, and 4) interpersonal factors/relationships. To determine the extent to which these themes exist in the wider communities of developed and developing nations, the reviewers then abstracted data from the survey studies to determine if the issues addressed in the qualitative studies had been asked about in the surveys. We abstracted data on the prevalence of the issues as reported in the surveys.

We extracted data on the quality of both qualitative and quantitative studies using pre-determined criteria for quality. We previously reported our rationale for assessing the quality of qualitative studies and in this study have extended our quality assessment to examine quantitative surveys.¹³ Although no formal criteria exist for appraising the quality of surveys, we a priori determined that the following criteria are important across surveys: 1) the survey included members of the target community in the preparation of the survey tool, 2) the survey instrument was assessed for face validity, 3) the survey population was randomly selected, 4) a rationale for determining the response rate was provided, and 4) the investigators attempted to contact non-responders. We did not propose a cut-off score for higher-quality surveys versus lower-quality surveys.

Statistical Analysis

We measured chance-adjusted inter-rater agreement for eligibility using the K statistic. When information on proportions was available in the quantitative studies, we first stabilized the variances of the raw proportions (r/n) using a Freeman-Tukey-type arcsine square-root transformation,¹⁴ and then conducted weighted analysis of studies using methods described by Fleiss.¹⁵ The pooled proportion is calculated as the back-transform of the weighted mean of the transformed proportions, using inverse arcsine variance weights for the fixed-effects model and DerSimonian-Laird weights for the random-effects model. The random-effects model recognizes that the studies are a sample of all potential studies and incorporates an additional between-study component to the estimate of variability.¹⁶ Thus, larger studies with smaller variances have relatively more impact on the final estimate. We present the weighted mean with 95% confidence intervals, with lower confidence intervals truncated at zero. The I2 statistic was calculated as a measure of the proportion of the overall variation in the meta-analyses that was attributable to between-study heterogeneity.¹⁷

Results

Study Selection and Characteristics

The primary literature search produced 228 studies. There was near-perfect agreement on choosing the 115 applicable studies from the reviewed abstracts (K>0.8). Of these, 31 were excluded as they were either not original studies or did not examine factors that influence adherence to ART. The remaining 84 studies were included in our analysis (Figure 1). All studies were published in English.

Thirty-seven of the studies were qualitative (Table 1). Twelve used focus groups (total number of patients, n=415),^18-29 15 used semi-structured interviews (n=729),^30-44 and nine used open-ended questioning (n = 694)^45-53 to explore barriers and facilitators to adherence. One study employed a writing intervention to solicit barriers and motivators to adherence.⁵⁴ The 47 remaining studies employed a quantitative methodology (surveys) and used structured questionnaires or structured interviews (total n=12,902)^4,55-100 to determine potential factors. No studies reported following up with non-responders to the surveys. Of the total sample of eligible studies, 72 were conducted in developed countries,^{4,18-25,30-39,44-46,48-50,53-56,58,59,61,62,64-67,69-76,79-81, 83,84,86,87,108} and 12 in developing nations.^{47,52,57,60,63,68,77,78,82,85,94,96} Fifty-six were from the United States,^{4,18-26,28,30-36,38-40,46,49-51,53,54,58,59,61,62,66,67,70,71, 73,74,76,79-81,84,86,88-91,93,95,108} three from Canada,^27,45,72 three from the United Kingdom,^55,69,98 two from Italy,^56,64 two from France,^75,92 two from The Netherlands,^42,83 and one each from Australia,⁴⁸ Switzerland,³⁷ and Belgium.⁴⁴ Two studies were multinational.^65,87 The studies conducted in developing countries included four from Brazil,^47,68,78,85 and one each from Uganda,⁵⁷ Côte d'Ivoire,⁶³ South Africa,⁸² Malawi,⁹⁶ Botswana,⁵² Costa Rica,⁹⁴ Romania,⁶⁰ and China.⁷⁷

Barriers and Facilitators (Developed Countries): Themes From Qualitative Studies

Barriers. Thirty-three individual themes of barriers were recorded in 34 qualitative studies.

• Patient-related: Thirteen barriers were patient-related and included: a fear of disclosure and wanting to avoid taking medications in public places (23/34);^{18-20,22-25,27-29,31-33,35-37,40,42,44,45,49-51,108} feeling depressed, hopeless, or overwhelmed (18/34);^{19,23-26,29,31,33,36,40,41,43,45,46,49,50} having a concurrent addiction (14/34);^{23,24,27,31,33,36,39-42,49-51,81} and forgetting to take medication at the specified time (11/34).^{20,24,25,28,31-33,37,40,44,50} Other barriers include: being suspicious of treatment/medical establishment (9/34);^{21,26,35,36,38,41,42,50,51} wanting to be free of medications or preferring a natural approach (10/34);^{20,21,29,31,32,37,44,50,54,108} feeling that treatment is a reminder of HIV status (8/34);^{18,32,38,39,41,43,49,54} wanting to be in control (7/34);^{28,31,37,38,41,54,108} not understanding treatment instructions (5/34);^{31,33,36,38,42} still having doubt or not being able to accept HIV status (5/34);^{18,33,42,44,51} and a lack of self-worth (4/34).^35,43,44,51 Financial constraints,^31,42,46 being homeless,^40,42 and having other concurrent illnesses affecting adherence were also cited.

• Beliefs about medication: There were eight reported barriers pertaining to beliefs/perceptions about medications. Some common barriers in this category included: side effects (either real or anticipated) (27/34);^{18,20,21,23-32,35,37,38,41-46,48-50,54,108} complicated regimens (12/34);^{18,22,23,26-28,32,42,48-50,54} and the taste, size, dosing frequency, and/or pill count (12/34).^{18,20,23-25,29,45,48-50,54} In nine studies, when patients prescribed HAART felt healthy, adherence was often negatively affected.^{22,24,25,29,32,33,38,43,44} Other barriers included: doubting the efficacy of HAART (7/34);^{21,23,25,26,42,45,46} having a decreased quality of life (6/34);^{20,24,25,38,42,46} uncertainty of long-term effects (6/34);^{30,32,45,46,48,49} and unwanted changes in body image (5/34).^{18,28,37,45,54}

• Daily schedules: Nine common barriers were related to daily schedules and included: disruptions in routine or having a chaotic schedule (16/34);^{19,22,23,25,27,30,37,39-45,54,108} finding HAART too inconvenient or difficult to incorporate (14/34);^{19,20,27-29,31,32,37,38,41,44,46,48,54,108} and difficulties coordinating adherence with work, family, or care-giving responsibilities (11/34).^{18,20,24,27,28,31,32,37,45,54} Individuals in seven studies found it difficult to balance the numerous strict dietary requirements associated with HAART.^{18,19,22,25,30,39,45} Six studies cited sleeping through a dose.^{19,29,31,39,40,49} Other barriers included: being away from home and not bringing medication (6/34);^{24,31,33,39,40,42} being too distracted or busy (5/34);^{24,29,33,40,51} and having no time to refill prescriptions, or other pharmacy-related problems (4/34).^22,24,25,31 Finally, four studies described difficulties with a particular dose, particularly the middle-of-day or early-morning dose.^19,29,42,48

• Interpersonal relationships: Interpersonal relationships can affect adherence behaviors. Twelve studies noted a lack of trust or a dislike of a patient's health care provider as an impediment to adherence.^{21-24,27,31,34,36,38,42,49,50} Ten studies noted social isolation.^{23,25,33,36,42,44,48-51} Nine studies noted negative publicity regarding HAART or the medical establishment.^{21,28,35,36,38,44-46,51} Finally, five studies noted that having a discouraging social network often deterred patients from successful adherence (5/34).^{21,23,28,35,45}

Facilitators. Fourteen factors facilitating successful adherence to HAART were abstracted.

• Patient-related: Patient-related facilitators included having self-worth (15/23),^{19,23,26,28,29,32,36,41,42,44,45,49-51,53} medication taking priority over substance use (4/23),^23,36,40,42 and seeing positive results when adhering to HAART (6/23).^{24,26,28,32,45,50} Also, those patients who had accepted their HIV-seropositivity reported improved adherence (8/23).^{18,28,29,32,41,44,49,51}

• Beliefs about medication: The most common motivator (12/23) to adherence is a belief in the efficacy of HAART and "having faith" in the treatment.^{18,19,21-24,42,44,45,49,50,53} Other motivators included understanding the need for strict compliance (9/23),^{18,24,26,28,30,32,36,42,44} and having a simple regimen (3/23).^18,21,49

• Daily schedules: Twelve studies reported learning to balance HAART with daily schedules as a facilitator of adherence. Having a routine in which taking antiretrovirals could be easily incorporated (11/23),^{22,23,26,30,32,36,40,42,44,45,49} and making use of reminder tools (7/23)^{18,22,23,40,42,44,49} are both reported to be effective tools for optimizing adherence.

• Interpersonal relationships: Positive interpersonal relationships were reported as necessary for successful adherence. Having a trusting relationship with a health care provider was reported as a facilitator of adherence in 17 studies.^{18,19,21-24,28,29,32,34,36,42,44,45,49-51,53,108} In addition, openly disclosing HIV status to family and friends and having a strong support network was reported as influential to adherence (18/23).^{18,19,22,23,26,30,32,35,36,40,42-45,49-51,53} Other motivators included: living for someone, especially, children (9/23);^{19,21,23,26,28,43,45,50,51} being actively involved in treatment decision making (4/23);^18,22,34,36 and using friends and family as reminders (6/23).^{18,19,23,35,40,53}

Common Themes From Surveys and Quantitative Studies

Figure 2 displays the pooled results of studies assessing barriers and reporting proportions of responders. There were three barriers described in qualitative reports but not in the quantitative studies. These were: having suspicions regarding HAART, wanting to be in control, and doubting or having difficulty accepting one's HIV status.

Eight quantitative studies reported facilitators to adherence. Four themes for facilitation of adherence were mentioned in the qualitative studies that were not discussed in the relevant quantitative studies (i.e., having medication take priority over substance abuse, having a simple regimen, using reminder tools, and living for someone).

Barriers (Developing Countries): Themes From Qualitative Studies

As there were only two studies identified, we describe the findings here. Eighteen specific barriers are cited in two studies.^47,52

• Patient-related: The most common patient-related barriers were: having a co-existing substance addiction, simply forgetting, and financial constraints.^47,52 Other barriers affecting adherence incorporated: a fear of disclosure;⁵² difficulty understanding both treatment instructions and the need for compliance;⁴⁷ and the presence of concurrent diseases or illnesses, including malnutrition.⁵²

• Beliefs about medication: Barriers reflective of patient beliefs regarding antiretrovirals included: side effects (either real or anticipated);⁵² complicated regimens;⁵² taste, size, and frequency of dosing;⁵² having doubts about HAART efficacy;⁴⁷ feeling fine or healthy;⁵² a decreased quality of life while taking medications, or feeling too sick;⁵² and being uncertain about potential long-term effects of HIV treatment.⁴⁷

• Daily schedules: Trouble incorporating work and family responsibilities with HAART was seen as a barrier to adherence in both studies. Traveling long distances to receive treatment was common, and not surprisingly, transportation difficulties were often reported to be a major hindrance to adherence (2/2). Other barriers included running out of medications or having an irregular supply;⁵² being away from home;⁵² and being too busy or distracted to properly comply.⁵²

No studies mentioned interpersonal relationships as a barrier to adherence in this population. No facilitators to adherence were discussed in any study in a developing country setting.

Themes From Surveys and Quantitative Studies

Ten surveys were found in developing country settings (Figure 3). No quantitative study enquired of difficulties with morning or afternoon doses, work and family responsibilities, or listed inconvenience as a barrier.

Discussion

To our knowledge, this is the first systematic review to examine the concerns of HIV-positive patients to maintaining adherence. We found that fear of disclosure, forgetfulness, a lack of understanding of treatment benefits, complicated regimens, and being away from their medications were consistent barriers to adherence across developed and developing nations. More common to developing settings were issues of access, including financial constraints and a disruption in access to medications. While there is a tremendous paucity of qualitative research in developing settings, our findings indicate that many barriers to adherence can be addressed with patients through discussion and education regarding treatment benefits to health. In developing settings, access to medications is the greatest concern. Indeed, discussion in both economic settings may alleviate patients' suspicions regarding treatment and address practical barriers to improve adherence. This study should also be used to guide the development of interventions aiming to improve adherence in any setting.

This study has several important strengths. The methods we employed to tabulate these findings come from a multi-step process. We first systematically identified qualitative and quantitative studies examining the questions. We then extracted the themes from the qualitative studies and determined which of them were sampled in the quantitative studies. Finally, we synthesized the available quantitative data. By systematically determining the existence and prevalence of barriers in multiple qualitative and quantitative studies, we believe that stronger inferences can be made into patient-related adherence obstacles and facilitators. We have previously demonstrated that surveys benefit from systematically examining qualitative studies, as this improves content validity.^13,101 To this end, our review of qualitative studies identified several key themes addressing barriers to adherence that were not examined in larger quantitative studies. The presence of barriers in more than one qualitative study, consisting of populations of patients representing different patient populations, supports the conclusion that these barriers are somewhat applicable. Our meta-analysis of survey data is a relatively new process that we have previously demonstrated,^102,103 and can permit stronger inferences into the generalizability of our findings. Finally, our criteria to assess the quality of both qualitative studies and surveys are a new contribution to the methodological literature. Recognizing that the absence of reporting particular methodological criteria may not reflect what was actually conducted during a study,¹⁰⁴ we invite discussion regarding the relative usefulness and applicability of these criteria.

This work has several limitations. We aimed to reduce reviewer bias by conducting abstraction independently, in duplicate. We cannot, however, know to what extent we may miss themes or to what extent reporting bias of the original report may have contributed. We emphasize that our methodology is specific but not sensitive for identifying themes. Reporting bias in the included manuscripts may have limited our ability to identify all barriers and facilitators to adherence. A broad range of economic and social conditions fall under the HDI. It would be wrong to assume that all individuals living in a HDI-categorized "developed" nation are in a better economic situation than all individuals living in a "developing" nation. Detailed information pertaining to this was rarely available in the original reports included in this review. It is possible that surveys used in developing nations were similar to surveys used in developed nations. However, the validity of these surveys in developing settings may not be appropriate, and we press for further qualitative research on this topic. Detailed population descriptions (e.g., education level) and the regional conditions from which this study is produced (e.g., gross national product) would benefit interpretation of future studies in this field. There are several interpretations of appropriate adherence and execution of drug regimens. We did not evaluate patients' perceptions of what "adherence" means to them, whether it meant acceptance, execution, or persistence of drug therapy.¹⁰⁵ In our meta-analyses of pooled survey data, we found large heterogeneity (as displayed by the I2 values in Figures 2 and 3), indicating large variation between the surveys. Very little methodological literature deals with pooling proportions, and our findings call for further exploration to determine the importance of this heterogeneity. Finally, there were few studies in developing countries that examined early adopters to ART. These individuals may not be representative of the larger epidemic and may not have experienced longer-term side effects of therapy.

It is important to note that the qualitative studies generated a richer spectrum of barriers and facilitators than did the quantitative studies. Qualitative studies are superior at identifying patient-important barriers and facilitators. We would submit that the ideal study of adherence would be one that occurs across several phases and incorporates both qualitative and quantitative elements. For example, to avoid biasing one's investigation with a priori assumptions about what may be important factors relating to adherence in a given population, it is logical to commence a study with qualitative research, thereby allowing the local population to tell the researchers what they believe to be important barriers, rather than the reverse. By using questionnaires developed in settings that are economically or culturally foreseeably different, the surveys force respondents to answer potentially irrelevant questions.

Clearly, the evidence base for barriers and facilitators of adherence is far richer from developed countries than from developing countries. In our analysis we found only two qualitative studies published from developing nation settings. This is sadly paradoxical, given that the vast majority of HIV-positive patients live in the developing world, and over the coming decades will constitute a growing proportion, and probably the majority, of the world's HAART recipients. Consequently, we see further research on HAART adherence in developing countries that incorporates both qualitative and quantitative elements as a priority.

Our findings should influence adherence program delivery systems in developing settings. We found that issues such as fear of disclosure, suspicions about treatment, forgetfulness, and irregular supply were important barriers identified by large proportions of the populations studied. It seems appropriate that before mandating any adherence program, such as disclosure or accompagnateurs, opportunities should be provided for individuals who require opting out.^106,107 Further, in developing settings, the reliability of medication access is an important adherence barrier that individuals have little opportunity to facilitate. Patient-level adherence can be determined only when a steady supply of medication exists.

We identified a broad range of barriers and facilitators to adherence. These barriers should be inferred as guides for interventional research to improve adherence rates. Given the many factors tabulated in this review, clinicians should use this information to engage in open discussion with patients to promote adherence and identify barriers and facilitators within their own populations. The methodology we used to pool the quantitative data is novel and may prove a useful methodological tool for generalizing patient-important issues.

Editor's Note: Reprinted with permission from PLoS Medicine (first e-published November 21, 2006).

References

1. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.

2. Mannheimer SB, Matts J, Telzak E, et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2005;1:10-22.

3. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;1:47-58.

4. Ferguson T, Stewart KE, Funkhouser E, et al. (2002) Patient-percieved barriers to antiretroviral adherence: Associations with race. AIDS Care. 2002;5:607-617.

5. Friedland G, Williams A. Attaining higher goals in HIV treatment: The central importance of adherence. AIDS. 1999;(Suppl 1):S61-S72.

6. Paterson DL, Swindells S, Mohr J, et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;1:21-30.

7. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;4:357-366.

8. Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS. 2003;13:1925-1932.

9. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2000;9:1181-1183.

10. Wood E, Hogg RS, Yip B, et al. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS. 2003;5: 711-720.

11. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: A meta-analysis. JAMA. 2006;6:679-690.

12. United Nations Development Programme (2004) Human Development Reports Accessed October 4, 2006, at http://hdr.undp.org.

13. Mills E, Jadad AR, Ross C, Wilson K. Systematic review of qualitative studies exploring parental beliefs and attitudes toward childhood vaccination identifies common barriers to vaccination. J Clin Epidemiol. 2005;11:1081-1088.

14. Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat. 1950;607-611.

15. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res. 1993;2:121-145.

16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;3:177-188.

17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;11:1539-1558.

18. Abel E, Painter L. Factors that influence adherence to HIV medications: Perceptions of women and health care providers. J Assoc Nurses AIDS Care. 2003;4:61-69.

19. Golin C, Isasi F, Bontempi JB, Eng E. Secret pills: HIV-positive patients' experiences taking antiretroviral therapy in North Carolina. AIDS Educ Prev. 2002;4:318-329.

20. Miller L, Huffman HB, Weidmer BA, Hays RD. Patient preferences regarding antiretroviral therapy. Int J STD AIDS. 2002;13:593-601.

21. Misener T, Sowell RL. HIV-infected women's decisions to take antiretrovirals. West J Nurs Res. 1998;4:431-447.

22. Murphy D, Johnston Roberts K, et al. Barriers to antiretroviral adherence among HIV-infected adults. AIDS Patient Care STDS. 2000;1:47-58.

23. Murphy D, Johnston Roberts K, et al. Barriers and successful strategies to antiretroviral adherence among HIV-infected monolingual Spanish-speaking patients. AIDS Care. 2003;2:217-230.

24. Powell-Cope G, White J, Henkelman EJ, Turner BJ. Qualitative and quantitative assessments of HAART adherence of substance abusing women. AIDS Care. 2003;2:239-249.

25. Proctor V, Tesfa A, Tompkins DC. Barriers to adherence to highly active antiretroviral therapy as expressed by people living with HIV/AIDS. AIDS Patient Care STDS. 1999;9:535-544.

26. Richter D, Sowell RL, Pluto DM. Attitudes toward antiretroviral therapy among African American women. Am J Health Behav. 2002;1:25-33.

27. Schilder A, Kennedy C, Goldstone IL, et al. "Being dealt with as a whole person." Care seeking and adherence: The benefits of culturally competent care. Soc Sci Med. 2001;52:1643-1659.

28. Stone V, Clarke J, Lovell J, et al. (1998) HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med. 1998;13:586-593.

29. Westerfelt A. A qualitative investigation of adherence issues for men who are HIV positive. Social Work. 2004;2:231-240.

30. Adamian M, Golin CE, Shain LS, DeVellis B. Brief motivational interviewing to improve adherence to antiretroviral therapy: Development and qualitative plot assessment of an intervention. AIDS Patient Care STDS. 2004;4:229-238.

31. Barton Laws M, Wilson IB, Bowser DM, Kerr SE. Taking antiretroviral therapy for HIV infection: Learning from patients' stories. J Gen Intern Med. 2000;15:848-858.

32. Graney M, Bunting SM, Russell CK. HIV/AIDS medication adherence factors: Inner-city clinic patients' self-reports. Tenn Med. 2003;2:73-78.

33. Hill Z, Kendall C, Fernandez M. Patterns of adherence to antiretrovirals: Why adherence has no simple measure. AIDS Patient Care STDS. 2003;10:519-525.

34. Johnston Roberts K. Physician-patient relationships, patient satisfaction and antiretroviral medication adherence among HIV-infected adults attending a public health clinic. AIDS Patient Care STDS. 2002;1:43-50.

35. Klitzman R, Kirshenbaum SB, Dodge B, et al. Intricacies and inter-relationships between HIV disclosure and HAART: A qualitative study. AIDS Care. 2004;5:628-640.

36. Malcolm S, Ng JJ, Rosen RK, Stone VE. An examination of HIV/AIDS patients who have excellent adherence to HAART. AIDS Care. 2003;2:251-261.

37. Meystre-Agustoni G, Dubois-Arber F, Cochand P, Telenti A. (2000) Antiretroviral therapies from the patient's perspective. AIDS Care. 2000;6:717-721.

38. Oggins J. Notions of HIV and medication among multiethnic people living with HIV. Health Social Work. 2003;1:53-63.

39. Reback C, Larkins S, Shoptaw S. Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care. 2003;6:775-785.

40. Ryan G, Wagner GJ. Pill taking 'routinization': A critical factor to understanding episodic medication adherence. AIDS Care. 2003;6:795-806.

41. Wilson H, Hutchinson SA, Holzemer WL. Reconciling incompatibilities: A grounded theory of HIV medication adherence and symptom management. Qual Health Res. 2002;10:1309-1322.

42. Witteveen E, van Ameijden EJC. Drug users and HIV-combination therapy (HAART): Factors with impede or facilitate adherence. Subst Use Misuse. 2002;14:1905-1925.

43. Wood S, Tobias C, McCree J. Medication adherence for HIV positive women caring for children: In their own words. AIDS Care. 2004;7:909-913.

44. Hammami N, Nostlinger C, Hoeree T, et al. Integrating adherence to highly active antiretroviral therapy into children's daily lives: A qualitative study. Pediatrics. 2004;5:e591-e597.

45. Adam B, Maticka-Tyndale E, Cohen JJ. Adherence practices among people living with HIV. AIDS Care. 2003;2:263-274.

46. Aversa S, Kimberlin C. Psychosocial aspects of antiretroviral medication use among HIV patients. Patient Educ Couns. 1996;29:207-219.

47. Brigido L, Rodrigues R, Casseb J, et al. Impact of adherence to antiretroviral therapy in HIV-1-infected patients at a university public service in Brazil. AIDS Patient Care STDS. 2001;11:587-593.

48. Goode M, McMaugh A, Crisp J, Wales S. Adherence issues in children and adolescents receiving highly active antiretroviral therapy. AIDS Care. 2003;3:403-408.

49. Kemppainen J, Levine R, Buffum M, et al. Antiretroviral adherence in persons with HIV/AIDS and severe mental illness. J Nerv Ment Dis. 2004;192:395-404.

50. Remien R, Hirky AE, Johnson MO, et al. Adherence to medication treatment: A qualitative study of facilitators and barriers among a diverse sample of HIV+ men and women in four US cities. AIDS Behavior. 2003;1:61-72.

51. Sankar A, Luborsky M, Schuman P, Roberts G. Adherence discourse among African-American women taking HAART. AIDS Care. 2002;2:203-218.

52. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003;3:281-288.

53. Ka'opua L, Mueller CW. Treatment adherence among Native Hawaiians living with HIV. Social Work. 2004;1:55-62.

54. Johnston Roberts K, Mann T. Barriers to antiretroviral medication adherence in HIV-infected women. AIDS Care. 2000;4:377-386.

55. Brook M, Dale A, Tomlinson D, et al. Adherence to highly active antiretroviral therapy in the real world: Experience of twelve English HIV units. AIDS Patient Care STDS. 2001;9:491-494.

56. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;5:445-449.

57. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, et al. Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int J STD AIDS. 2005;16:38-41.

58. Catz S, Kelly JA, Bogart LM, et al. Patterns, correlates and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;2:124-133.

59. Chesney M, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. AIDS Care. 2000;3:255-266.

60. Cupsa A, Ghenonea C, Bulucea D, Dinescu S. Factors with a negative influence on compliance to antiretroviral therapies. Ann N Y Acad Sci. 2000;918:351-354.

61. Eldred L, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;2:117-125.

62. Erlen J, Sereika SM, Cook RL, Hunt SC. Adherence to antiretroviral therapy among women with HIV infection. J Obstet Gynecol Neonatal Nurs. 2002;31:470-477.

63. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1 infected children in Abidjan, Côte d'Ivoire. AIDS. 2004;18:1905-1913.

64. Giacomet V, Albano F, Starace F, et al. Adherence to antiretroviral therapy and its determinants in children with human immunodeficiency virus infection: A multicenter, national study. Acta Paediatr. 2003;92:1398-1402.

65. Gibb D, Goodall RL, Giacomet V, et al. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatr Infect Dis J. 2003;22:56-62.

66. Harzke A, Williams ML, Nilsson-Schonnesson L, et al. Psychosocial factors associated with adherence to antiretroviral medications in a sample of HIV-positive African American drug users. AIDS Care. 2004;4:458-470.

67. Heckman B, Catz SL, Heckman TG, et al. Adherence to antiretroviral therapy in rural persons living with HIV disease in the United States. AIDS Care. 2004;2:219-230.

68. Hofer C, Schechter M, Harrison LH. Effectiveness of antiretroviral therapy among patients who attend public HIV clinics in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr. 2004;4:967-971.

69. Horne R, Buick D, Fisher M, et al. Doubts about necessity and concerns about adverse effects: Identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS. 2004;15:38-44.

70. Johnson M, Catz SL, Remien RH, et al. Theory-guided, empirically supported avenues for intervention on HIV medication nonadherence: Findings from the healthy living project. AIDS Patient Care STDS. 2003;12:645-656.

71. Kalichman S, Catz S, Ramachandran B. Barriers to HIV/AIDS treatment and treatment adherence among African-American adults with disadvantaged education. J Natl Med Assoc. 1999;91:439-446.

72. Kerr T, Palepu A, Barnes G, et al. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. Antiviral Ther. 1999;9:407-414.

73. Kleeberger C, Phair JP, Strathdee SA, et al. Determinants of heterogenous adherence to HIV-antiretroviral therapies in the multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26:82-92.

74. Marhefka S, Farley JJ, Rodrigue JR, et al. Clinical assessment of medication adherence among HIVinfected children: Examination of the Treatment Interview Protocol (TIP). AIDS Care. 2004;3:323-337.

75. Moatti J, Carrieri MP, Spire B, et al. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. AIDS. 2000;14:151-155.

76. Mohammed H, Kieltyka L, Richardson-Alston G, et al. Adherence to HAART among HIV-infected persons in rural Louisiana. AIDS Patient Care STDS. 2004;5:289-296.

77. Molassiotis A, Nahas-Lopez V, Chung WY, et al. Factors associated with adherence to antiretroviral medication in HIV-infected patients. Int J STD AIDS. 2002;13:301-310.

78. Monreal M, da Cunha RV, Trinca LA. Compliance to antiretroviral medication as reported by AIDS patients assisted at the University Hospital of the Federal University of Mato Grosso do Sul. Braz J Infect Dis. 2002;1:8-14.

79. Mostashari F, Riley E, Selwyn PA, Altice FL. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;4:341-348.

80. Muma R, Ross MW, Parcel GS, Pollard RB. Zidovudine adherence among individuals with HIV infection. AIDS Care. 1995;4:439-447.

81. Murphy D, Sarr M, Durako SJ, et al. Barriers to HAART adherence among human immunodeficiency virusinfected adults. Arch Pediatr Adolesc Med. 2003;157:249-255.

82. Nachega J, Stein DM, Lehman DA, et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses. 2004;10:1053-1056.

83. Nieuwkerk P, Sprangers MA, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med. 2001;161:1962-1968.

84. Palmer N, Salcedo J, Miller AL, Winiarski M, Arno P. Psychiatric and social barriers to HIV medication adherence in a triply diagnosed methadone population. AIDS Patient Care STDS. 2003;12:635-644.

85. Pinheiro C, de-Carvalho-Leite JC, Drachler ML, Silveira VL. (2002) Factors associated with adherence to antiretroviral therapy in HIV/AIDS patients: A cross-sectional study in Southern Brazil. Braz J Med Biol Res. 2002;35:1173-1181.

86. Reddington C, Cohen J, Baldillo A, et al. Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J. 2000;19:1148-1153.

87. Reynolds N, Testa MA, Marc LG, et al. Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: A multicenter, cross-sectional study. AIDS Behavior. 2004;2:141-150.

88. Savini C, James CW, DiGuglielmo DJ. Survey of patient and clinician attitudes on adherence in a rural HIV clinic. J Assoc Nurses AIDS Care. 2003;3: 72-75.

89. Schneider J, Kaplan SH, Greenfield S, Li W, Wilson IB. Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection. J Gen Intern Med. 2004;19:1096-1103.

90. Siegel K, Karus D, Schrimshaw EW. Racial differences in attitude toward protease inhibitors among older HIV-infected men. AIDS Care. 2000;4:423-434.

91. Simoni J, Frick PA, Lockhart D, Liebovitz D. Mediators of social support and antiretroviral adherence among an indigent population in New York City. AIDS Patient Care STDS. 2002;9:431-439.

92. Spire B, Duran S, Souville M, et al. Adherence to highly active antiretroviral therapies (HAART) in HIVinfected patients: From a predictive to a dynamic approach. Soc Sci Med. 2002;54:1481-1496.

93. Stein M, Rich JD, Maksad J, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: Effect of ongoing illicit drug use. Am J Drug Alcohol Abuse. 2000;2:195-205.

94. Stout B, Leon MP, Niccolai LM. Nonadherence to antiretroviral therapy in HIV-positive patients in Costa Rica. AIDS Patient Care STDS. 2004;5:297-304.

95. Tucker JS, Orlando M, Burnam MA, Sherbourne CD, Kung FY, et al. Psychosocial mediators of antiretroviral nonadherence in HIV-positive adults with substance use and mental health problems. Health Psychol. 2004;4:363-370.

96. van Oosterhout JJ, Bodasing N, Kumwenda JJ, et al. Evalution of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health. 2005;5:464-470.

97. Wagner G, Kanouse DE, Koegel P, Sullivan G. Correlates of HIV antiretroviral adherence in persons with serious mental illness. AIDS Care. 2004;4:501-506.

98. Walsh J, Horne R, Dalton M, Burgess AP, Gazzard BG. Reasons for non-adherence to antiretroviral therapy: Patients' perspectives provide evidence of multiple causes. AIDS Care. 2001;6:709-720.

99. Weidle PJ, Ganera CE, Irwin KL, et al. Adherence to antiretroviral medications in an inner city population. J Acquir Immune Defic Syndr. 1999;5:498-502.

100. Wilson TE, Ickovics JR, Fernandez MI, et al. Self-reported zidovudine adherence among pregnant women with human immunodeficiency virus infection in four US states. Am J Obstet Gynecol. 2001;184:1235-1240.

101. Mills EJ, Montori VM, Ross CP, et al. Systematically reviewing qualitative studies complements survey design: An exploratory study of barriers to paediatric immunisations. J Clin Epidemiol. 2005;11:1101-1108.

102. Mills E, Wilson K, Rachlis B, et al. Barriers to participation in HIV drug trials: A systematic review. Lancet Infect Dis. 2006;1:32-38.

103. Mills EJ, Seely D, Rachlis B, et al. Barriers to participation in clinical trials of cancer: A meta-analysis and systematic review of patient-reported factors. Lancet Oncol. 2006;2:141-148.

104. Devereaux PJ, Choi PT, El-Dika S, et al. An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methods. J Clin Epidemiol. 2004;12:1232-1236.

105. Urquhart J, Vrijens B. New findings about patient adherence to prescribed drug dosing regimens: An introduction to pharmionics. Eur J Hosp Pharm Sci. 2005;55:103-106.

106. Liechty CA, Bangsberg DR. Doubts about DOT: Antiretroviral therapy for resource-poor countries. AIDS. 2003;9:1383-1387.

107. Farmer P, Leandre F, Mukherjee J, et al. Community-based treatment of advanced HIV disease: Introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull World Health Organ. 2001;12:1145-1151.

108. Johnston-Roberts K, Mann T. Adherence to antiretroviral medications in HIV/AIDS Care: A narrative exploration of one woman's foray into intentional nonadherence. Health Care Women Int. 2003;24:552-564.